MedicineEurope PMC
Heuristic editor, no API keyVerdict: NotableSurvival benefit of guideline-directed medical therapy in older patients with heart failure: a systematic review and meta-analysis
Background Heart failure-related mortality in older patients has increased.
Key numbers
- 95% CI were analysed
VerdictWorth a reader's time today.
Abstract
Background Heart failure-related mortality in older patients has increased. Guideline-directed medical therapy (GDMT) in heart failure with reduced ejection fraction (HFrEF) remains insufficient in this population. This study assessed the survival benefit of GDMT in elderly patients aged ≥65 years old with HFrEF. Methods MEDLINE, EMBASE and Cochrane Library were searched from inception to 5 February 2025. Inclusion criteria were age ≥65 years old with HFrEF, GDMT vs no GDMT and reported survival data. Pooled prevalence, HR and risk ratio (RR) with 95% CI were analysed. Heterogeneity was further explored through subgroup analyses. We evaluated potential small-study effects using Begg's rank correlation test, Egger's regression test, funnel plot inspection and trim-and-fill analysis. Publication bias was analysed visually using a funnel plot. Results 34 studies with 92 916 patients from 1994 to 2024 were included. The GDMT group received three of the four main drug classes in three studies, two drug classes in four studies and at least one class in the remaining studies. There were no reported data on the survival benefits of older patients receiving four classes of GDMT. Frail older patients were less likely to receive GDMT (RR 0.63 (0.45-0.89), I2 50%, p=0.009). There was a survival benefit of GDMT in older patients with left ventricular (LV) systolic dysfunction (HR 0.69 (0.64-0.74) p<0.001, Tau2 0.03, I2 71%). Older patients receiving beta-blockers were more likely to develop bradycardia (RR 3.98 (2.72-5.82), p<0.001, I2 0%). There was no difference in hypotension, acute renal impairment and hypoglycaemia between the GDMT and control group. Conclusions The use of GDMT in older patients with LV systolic dysfunction was associated with a survival benefit. However, the presence of frailty may limit the successful implementation and tolerability of these therapies. High-quality studies are urgently needed to guide the development of novel strategies aimed at optimising the management of older, frail patients with LV systolic function.
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ██░░░ 2 | 10% | Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt). |
| Magnitude | █░░░░ 1 | 20% | Marginal: within noise or a few percent on a saturated benchmark. |
| Evidence | █████ 5 | 32% | Definitive: phase 3 randomized evidence on hard endpoints, multi-lab replication, or community verification at scale. |
| Novelty | █░░░░ 1 | 8% | A minor twist on a known approach. |
| Trajectory | ██░░░ 2 | 5% | Some room to improve with obvious engineering. |
| Stakes | ███░░ 3 | 25% | Meaningful benefit to many people within a few years. |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: novelty (open problem); design (placebo-controlled, meta-analysis); verification (confidence interval, p-value, error bars); stakes (mortality, major disease, prevention or cure). Red flags: review or survey.
How the score was computed
- Merit
- 5.9 / 10
- Adjusted merit
- 4.9 / 10
- Attention
- 48%
- Freshness
- 64%
- Citations4 (reference 20, via openalex, Sep 29, 2026, 23:37 UTC)
- Field-weighted citation impact10.2 (reference 3, via openalex, Sep 29, 2026, 23:37 UTC)